Merck & Co., Inc. (NYSE:MRK) stock traded in a volatile session on Thursday following its third-quarter earnings report and updated fiscal 2025 outlook.The pharma giant reported adjusted earnings per share of $2.58, surpassing consensus estimates of $2.35, a jump from $1.57 reported a year ago.Merck reported sales of $17.28 billion, a 4% increase year-over-year, and exceeded the analysts’ projections of $16.96 billion.Also Read: Merck’s New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Ca ...